Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2

被引：15

作者：

Bonhomme, Marie E. ^{[1
]}

Bonhomme, Cyrille J. ^{[1
]}

Strelow, Lisa ^{[1
]}

Chaudhari, Atul ^{[1
]}

Howlett, Adrienne ^{[1
]}

Breidenbach, Carl ^{[1
]}

Hester, Jack ^{[1
]}

Hammond, Christopher ^{[1
]}

Fuzy, Micheal ^{[1
]}

Harvey, Laura ^{[1
]}

Swanner, Vanessa ^{[1
]}

Ellis, Jeymie ^{[1
]}

Greway, Rebecca R. ^{[2
]}

Pisciella, Victoria A. ^{[2
]}

Green, Tina ^{[2
]}

Kierstead, Lisa ^{[1
]}

机构：

[1] Thermo Fisher Sci, Vaccine Sci Lab, PPD, Lab Serv, Richmond, VA 23229 USA

[2] Thermo Fisher Sci, Dept Lab Biostat, PPD, Richmond, VA USA

来源：

PLOS ONE | 2022年 / 17卷 / 02期

关键词：

D O I：

10.1371/journal.pone.0262922

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

To enable benchmarking of immunogenicity between candidate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, there is a need for standardized, validated immunogenicity assays. In this article, we report the design and criteria used to validate immunogenicity assays and the outcome of the validation of serologic and functional assays for the evaluation of functional immune response and antibody titers in human serum. A quantitative cell-based microneutralization (MNT) assay, utilizing a reference standard, for detecting anti-SARS-CoV-2 spike protein-neutralizing antibodies in human serum and Meso Scale Discovery's multiplex electrochemiluminescence (MSD ECL) assay for immunoglobulin G (IgG) antibodies to SARS-CoV-2 spike, nucleocapsid, and receptor-binding domain (RBD) proteins were assessed for precision, accuracy, dilutional linearity, selectivity, and specificity using pooled human serum from coronavirus disease 2019 (COVID-19)-confirmed recovered donors. Both assays met prespecified acceptance criteria for precision, relative accuracy, dilutional linearity, selectivity, and specificity. Both assays demonstrated high specificity for the different SARS-CoV-2 antigens or virus tested, and no significant cross-reactivity with seasonal coronaviruses. An evaluation to compare the neutralizing activity in the MNT assay to the IgG measured using the MSD ECL assay showed a strong correlation between the presence of neutralizing activity and amount of antibodies against the spike and RBD proteins in sera from both convalescent and vaccinated individuals. Finally, the MNT assay was calibrated to the WHO reference standard to enable reporting of results in international units, thus facilitating comparison of immunogenicity data generated by different assays and/or laboratories. The MSD ECL assay has previously been calibrated. In conclusion, these validated assays for the evaluation of functional immune response and antibody titers following SARS-CoV-2 vaccination could provide a relatively simple standardized approach for accurately comparing immune responses to different vaccines and/or vaccination regimens.

引用

页数：18

共 15 条

[1]

[Anonymous], 2012, USP 35-NF 30

[2] Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability [J].

Brouwer, Philip J. M. ;

Caniels, Tom G. ;

van der Straten, Karlijn ;

Snitselaar, Jonne L. ;

Aldon, Yoann ;

Bangaru, Sandhya ;

Torres, Jonathan L. ;

Okba, Nisreen M. A. ;

Claireaux, Mathieu ;

Kerster, Gius ;

Bentlage, Arthur E. H. ;

van Haaren, Marlies M. ;

Guerra, Denise ;

Burger, Judith A. ;

Schermer, Edith E. ;

Verheul, Kirsten D. ;

van der Velde, Niels ;

van der Kooi, Alex ;

van Schooten, Jelle ;

van Breemen, Marielle J. ;

Bijl, Tom P. L. ;

Sliepen, Kwinten ;

Aartse, Aafke ;

Derking, Ronald ;

Bontjer, Ilja ;

Kootstra, Neeltje A. ;

Wiersinga, W. Joost ;

Vidarsson, Gestur ;

Haagmans, Bart L. ;

Ward, Andrew B. ;

de Bree, Godelieve J. ;

Sanders, Rogier W. ;

van Gils, Marit J. .

SCIENCE, 2020, 369 (6504) :643-+

[3] A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine [J].

Chu, Laurence ;

McPhee, Roderick ;

Huang, Wenmei ;

Bennett, Hamilton ;

Pajon, Rolando ;

Nestorova, Biliana ;

Leav, Brett .

VACCINE, 2021, 39 (20) :2791-2799

[4] Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial [J].

Folegatti, Pedro M. ;

Ewer, Katie J. ;

Aley, Parvinder K. ;

Angus, Brian ;

Becker, Stephan ;

Belij-Rammerstorfer, Sandra ;

Bellamy, Duncan ;

Bibi, Sagida ;

Bittaye, Mustapha ;

Clutterbuck, Elizabeth A. ;

Dold, Christina ;

Faust, Saul N. ;

Finn, Adam ;

Flaxman, Amy L. ;

Hallis, Bassam ;

Heath, Paul ;

Jenkin, Daniel ;

Lazarus, Rajeka ;

Makinson, Rebecca ;

Minassian, Angela M. ;

Pollock, Katrina M. ;

Ramasamy, Maheshi ;

Robinson, Hannah ;

Snape, Matthew ;

Tarrant, Richard ;

Voysey, Merryn ;

Green, Catherine ;

Douglas, Alexander D. ;

Hill, Adrian V. S. ;

Lambe, Teresa ;

Gilbert, Sarah C. ;

Pollard, Andrew J. .

LANCET, 2020, 396 (10249) :467-478

[5] The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control [J].

Helmy, Yosra A. ;

Fawzy, Mohamed ;

Elaswad, Ahmed ;

Sobieh, Ahmed ;

Kenney, Scott P. ;

Shehata, Awad A. .

JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)

[6] An mRNA Vaccine against SARS-CoV-2-Preliminary Report [J].

Jackson, L. A. ;

Anderson, E. J. ;

Rouphael, N. G. ;

Roberts, P. C. ;

Makhene, M. ;

Coler, R. N. ;

McCullough, M. P. ;

Chappell, J. D. ;

Denison, M. R. ;

Stevens, L. J. ;

Pruijssers, A. J. ;

McDermott, A. ;

Flach, B. ;

Doria-Rose, N. A. ;

Corbett, K. S. ;

Morabito, K. M. ;

O'Dell, S. ;

Schmidt, S. D. ;

Swanson, P. A. ;

Padilla, M. ;

Mascola, J. R. ;

Neuzil, K. M. ;

Bennett, H. ;

Sun, W. ;

Peters, E. ;

Makowski, M. ;

Albert, J. ;

Cross, K. ;

Buchanan, W. ;

Pikaart-Tautges, R. ;

Ledgerwood, J. E. ;

Graham, B. S. ;

Beigel, J. H. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (20) :1920-1931

[7] Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus [J].

Korber, Bette ;

Fischer, Will M. ;

Gnanakaran, Sandrasegaram ;

Yoon, Hyejin ;

Theiler, James ;

Abfalterer, Werner ;

Hengartner, Nick ;

Giorgi, Elena E. ;

Bhattacharya, Tanmoy ;

Foley, Brian ;

Hastie, Kathryn M. ;

Parker, Matthew D. ;

Partridge, David G. ;

Evans, Cariad M. ;

Freeman, Timothy M. ;

de Silva, Thushan, I ;

McDanal, Charlene ;

Perez, Lautaro G. ;

Tang, Haili ;

Moon-Walker, Alex ;

Whelan, Sean P. ;

LaBranche, Celia C. ;

Saphire, Erica O. ;

Montefiori, David C. .

CELL, 2020, 182 (04) :812-+

[8] Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults [J].

Mulligan, Mark J. ;

Lyke, Kirsten E. ;

Kitchin, Nicholas ;

Absalon, Judith ;

Gurtman, Alejandra ;

Lockhart, Stephen ;

Neuzil, Kathleen ;

Raabe, Vanessa ;

Bailey, Ruth ;

Swanson, Kena A. ;

Li, Ping ;

Koury, Kenneth ;

Kalina, Warren ;

Cooper, David ;

Fontes-Garfias, Camila ;

Shi, Pei-Yong ;

Tuereci, Oezlem ;

Tompkins, Kristin R. ;

Walsh, Edward E. ;

Frenck, Robert ;

Falsey, Ann R. ;

Dormitzer, Philip R. ;

Gruber, William C. ;

Sahin, Ugur ;

Jansen, Kathrin U. .

NATURE, 2020, 586 (7830) :589-+

[9]

National Institute for Biological Standards and Control (NIBSC), 2021, NEW REPL WHO STAND G

[10] Keeping track of the SARS-CoV-2 vaccine pipeline [J].

Parker, Edward P. K. ;

Shrotri, Madhumita ;

Kampmann, Beate .

NATURE REVIEWS IMMUNOLOGY, 2020, 20 (11) :650-650

← 1 2 →